TFPI Antibodies

Santa Cruz Biotechnology features a diverse variety of TFPI monoclonal antibodies for studying tissue factor pathway inhibitor (TFPI). TFPI monoclonal antibodies support multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). TFPI plays a crucial role in regulating blood coagulation by inhibiting the tissue factor/factor VIIa complex, which prevents excessive thrombin generation. Understanding TFPI function is essential for cardiovascular research and cancer studies, as it influences both normal physiology and disease progression. TFPI research has revealed significant insights into blood clotting disorders and potential therapeutic approaches. Investigating TFPI's molecular mechanisms has opened new avenues for developing targeted treatments in cardiovascular medicine. Recent studies have highlighted TFPI's role in maintaining vascular homeostasis and its potential as a biomarker for various conditions. TFPI monoclonal antibodies from Santa Cruz Biotechnology enable researchers worldwide to advance our understanding of blood coagulation and contribute to developing new therapeutic strategies.